UBRELVY is first in a new class1,2

An oral acute treatment that works differently at a primary cause of migraine by blocking CGRP receptors without causing vasoconstriction.1,3

References

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2019. 2. Data on file. Allergan. 3. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350.